Jane Street
QNCX icon

Jane Street’s Quince Therapeutics QNCX Stock Holding History

Jane Street’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-115
Closed -$142K – 10621
2022
Q1 		$142K Sell
115
-334
-74% -$454K ﹤0.01% 9269
2021
Q4 		$1.13M Buy
449
+66
+17% +$403K ﹤0.01% 5644
2021
Q3 		$7.02M Buy
+383
New +$6.09M ﹤0.01% 2270

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street's QNCX Position: Q1 2026 in Review

Jane Street sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 2,605 shares — an estimated $1.75M sold.

Jane Street first reported a position in QNCX in Q3 2020 and held it in 8 quarters. The position peaked at $2.13M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Jane Street reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 2,605 Quince Therapeutics shares in Q1 2026, an estimated $1.75M.
  • Jane Street first reported a position in Quince Therapeutics in Q3 2020 and held it in 8 quarters.
  • Jane Street's Quince Therapeutics position peaked at $2.13M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.